Tag: case-control study

Posted on

Risk Factors for Pediatric Arachnoid Cyst Rupture/Hemorrhage: A Case-Control Study

Risk_Factors_for_Pediatric_Arachnoid_Cyst

As the availability of imaging modalities has increased, the finding of arachnoid cysts has become common. Accurate patient counseling regarding physical activity or risk factors for cyst rupture or hemorrhage has been hampered by the lack of definitive association studies.

OBJECTIVE: This case-control study evaluated factors that are associated with arachnoid cyst rupture (intracystic hemorrhage, adjacent subdural hematoma, or adjacent subdural hygroma) in pediatric patients with previously asymptomatic arachnoid cysts.

METHODS: Patients with arachnoid cysts and intracystic hemorrhage, adjacent subdural hygroma, or adjacent subdural hematoma treated at a single institution from 2005 to 2010 were retrospectively identified. Two unruptured/nonhemorrhagic controls were matched to each case based on patient age, sex, anatomical cyst location, and side. Risk factors evaluated included arachnoid cyst size, recent history of head trauma, and altitude at residence.

RESULTS: The proportion of imaged arachnoid cysts that presented either originally or subsequently with a rupture or hemorrhage was 6.0%. Larger cyst size, as defined by maximal cyst diameter, was significantly associated with cyst rupture/hemorrhage (P < .001). When dichotomized with a 5-cm cutoff, 9/13 larger cysts ruptured and/or hemorrhaged, whereas only 5/29 smaller cysts ruptured/hemorrhaged (odds ratio = 16.5 (confidence interval [2.5, N]). A recent history of head trauma was also significantly associated with the outcome (P < .001; odds ratio = 25.1 (confidence interval [4.0, N]). Altitude was not associated with arachnoid cyst rupture or hemorrhage.

CONCLUSION: This case-control study suggests that larger arachnoid cyst size and recent head trauma are risk factors for symptomatic arachnoid cyst rupture/hemorrhage.

Posted on

Prognosis of patients with multifocal glioblastoma

J Neurosurg 117:705–711, 2012

The prognosis of patients with glioblastoma who present with multifocal disease is not well documented. The objective of this study was to determine whether multifocal disease on initial presentation is associated with worse survival.

Methods. The authors retrospectively reviewed records of 368 patients with newly diagnosed glioblastoma and identified 47 patients with multifocal tumors. Each patient with a multifocal tumor was then matched with a patient with a solitary glioblastoma on the basis of age, Karnofsky Performance Scale (KPS) score, and extent of resection, using a propensity score matching methodology. Radiation and temozolomide treatments were also well matched between the 2 cohorts. Kaplan-Meier estimates and log-rank tests were used to compare patient survival.

Results. The incidence of multifocal tumors was 12.8% (47/368). The median age of patients with multifocal tumors was 61 years, 76.6% had KPS scores ≥ 70, and 87.2% underwent either a biopsy or partial resection of their tumors. The 47 patients with multifocal tumors were almost perfectly matched on the basis of age (p = 0.97), extent of resection (p = 1.0), and KPS score (p = 0.80) compared with 47 patients with a solitary glioblastoma. Age (> 65 years), partial resection or biopsy, and low KPS score (< 70) were associated with worse median survival within the multifocal group. In the multifocal group, 19 patients experienced tumor progression on postradiation therapy MRI, compared with 11 patients (26.8%) with tumor progression in the unifocal group (p = 0.08). Patients with multifocal tumors experienced a significantly shorter median overall survival of 6 months (95% CI 4–10 months), compared with the 11-month median survival (95% CI 10–19 months) of the matched solitary glioblastoma group (p = 0.02, log-rank test). Two-year survival rates were 4.3% for patients with multifocal tumors and 29.0% for the unifocal cohort. Patients with newly diagnosed multifocal tumors were found to have an almost 2-fold increase in the hazard of death compared with patients with solitary glioblastoma (hazard ratio 1.8, 95% CI 1.1–3.1; p = 0.02). Tumor samples were analyzed for expression of phosphorylated mitogen-activated protein kinase, phosphatase and tensin homolog, O6-methylguanine-DNA methyltransferase, laminin b1 and b2, as well as epidermal growth factor receptor amplification, and no significant differences in expression profile between the multifocal and solitary glioblastoma groups was found.

Conclusions. Patients with newly diagnosed multifocal glioblastoma on presentation experience significantly worse survival than patients with solitary glioblastoma. Patients with multifocal tumors continue to pose a therapeutic challenge in the temozolomide era and magnify the challenges faced while treating patients with malignant gliomas.

Posted on

Clinical Outcome of Treatments for Spinal Dural Arteriovenous Fistulas

Spine 2012 ; 37 : 482 – 488. DOI: 10.1097/BRS.0b013e31822670df

This study was a case series study using a prospective single-institute database for the treatment of spinal dural arteriovenous fi stulas (SDAVFs).

Objective. To evaluate clinical factors that infl uence the neurological outcomes of treatment for SDAVFs, which were obtained from the analysis of 21 patients treated in our institution, and to provide management recommendations based on the review of former major clinical studies including our own reported over the past 2 decades.

Summary of Background Data. Since 1977, when Kendall and Logue described the etiology of SDAVFs as hyperpressure of intrathecal veins due to an abnormal shunting from the arteries, treatment strategies have improved dramatically along with developments in neuroimaging, endovascular techniques and materials, and microsurgery based on the underlying pathophysiological process. However, therapeutic guidelines remain controversial.

Methods. Patients treated for SDAVFs from 2000 to 2008 were eligible. Age, sex, level of shunting, initial symptom, duration of symptom, the treatment method, and clinical symptoms before and 6 months after treatment were investigated.

Results. There were a total of 30 patients (18 male and 12 female), with a mean age of 59 years; 21 of them underwent treatment for the fi rst time. We conducted a univariate analysis using a logistic regression model, on age, sex, the level of SDAVFs, duration of symptoms, symptom (sensory or paralysis), and gait function and micturition before treatment, and the intervention method were set as variables to investigate the risk factors for motor deficit 6 months after the treatment. Only gait function before treatment was correlated with the motor deficit 6 months after treatment (odds ratio = 10.0; 95% confidence interval = 1.28–78.11, P = 0.03). From these results, intervention at an early stage would be the key to a preferable outcome of the treatment for SDAVFs.

Conclusion. The clinical status before treatment significantly influenced the clinical outcome after the treatment.

 

Proudly powered by WordPress